The Max Foundation and Friends of Max Strengthen Partnership

Hyderabad, India–

The Max Foundation (Max) and Friends of Max (FOM) proudly announce the formalization of their long standing collaboration supporting people living with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) in India. The two organizations signed a landmark Memorandum of Understanding (MOU) at the recent Friends of Max 2015 Leadership Summit attended by Max CEO, Pat Garcia-Gonzalez in Hyderabad on April 19th.

Viji Venkatesh, Max’s Head of India shares an historical perspective, “In 2003, leaders of Max’s team in India and community leaders agreed to collaborate on providing free support services to families affected by CML and GIST in the country. This collaboration resulted in the formation of Friends of Max, a Charitable Trust registered with the Charities Commissioner’s Office in Mumbai. Today, we celebrate our MOU signing to enable greater support to people living with CML and GIST across the country.”

Pat Garcia-Gonzalez of Max remarks, “Since its inception, Friends of Max has served as the patient support arm of The Max Foundation. We are a united force. We are grateful for our partnership of so many years and full of hope as we look ahead to how much we can accomplish together.”

About Friends of Max
Friends of Max is a charitable trust registered in India comprised of individuals impacted directly and indirectly by chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). With 18 chapters in cities across India, the trust aims to provide mutual support and education for its thousands of active members under the motto, “Together we share and learn”.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.

  • Invitation to iCMLf Forum for physicians attending ASH 2017

    Invitation to iCMLf Forum for physicians attending ASH 2017

    Join us at the iCMLf Forum for Physicians from Emerging Economic Regions on December 8th at ASH.

  • Welcoming our New Vice President of Development

    The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.